ATXI · Avenue Therapeutics, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“These factors individually and collectively cause substantial doubt about the Company's ability to continue as a going concern to exist within one year from the date of this report.”View the 10-Q filed Aug 7, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $1.4M | $0 | — | — | — | — | — | — | — | — | |
| $881K | $1.04M | $6.65M | $6.13M | $2.7M | $1.25M | $2.87M | $22.19M | $17.7M | $6.7M | $1.33M | |
| $2.22M | $3.65M | $4.64M | $4.18M | $5.35M | $2.48M | $2.35M | $3.07M | $4.12M | $3.62M | $997K | |
| — | $4.49M | $11.28M | — | — | — | — | — | — | — | — | |
| -$2.9M | -$3.08M | -$11.28M | -$14.54M | -$8.04M | -$3.74M | -$5.21M | -$26.27M | -$21.82M | -$11.42M | -$2.38M | |
| — | -219.59% | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $0 | $294K | $420K | |
| $93K | $121K | $176K | $126K | $20K | $7000 | $62K | $357K | $93K | $88K | $0 | |
| — | — | — | — | — | — | — | $0 | $175K | $0 | — | |
| — | $2000 | $0 | $0 | $0 | — | — | — | — | — | — | |
| -$2.78M | -$2.91M | -$11.65M | -$10.49M | -$3.55M | -$3.73M | -$5.15M | -$25.91M | -$21.55M | -$12.26M | -$3.18M | |
| — | -207.19% | — | — | — | — | — | — | — | — | — | |
| -$26K | -$38K | -$44K | -$111K | -$51K | $0 | — | — | — | — | — | |
| — | — | -$11.65M | -$10.38M | -$3.55M | — | — | — | — | — | — | |
| USD/shares | -$0.84 | -$0.93 | -$15.79 | -$73.48 | -$122.25 | -$247.50 | -$348.75 | — | — | — | — |
| USD/shares | — | — | — | — | — | -$247.50 | -$348.75 | — | — | — | — |
| shares | — | 3.13M | 1.3M | 141.22K | 29.14K | 15.11K | 14.67K | 13.97K | 9101.4836 | 5897.7218 | 2542.6898 |
| shares | — | — | — | — | 29.14K | 15.11K | 14.67K | 13.97K | 9101.4836 | 5897.7218 | 2542.6898 |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2023: $1.1M in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 73 similar-size Biotechnology companies (of 534 listed).